Comparative bacterial genomics and fish vaccinology: genomic and phenotypic analysis of Vibrio anguillarum isolated from lumpfish (Cyclopterus lumpus) and vaccine evaluation in sablefish (Anoplopoma fimbria) against Aeromonas salmonicida
Although aquaculture is the fastest growing food-producing industry in the world, it is negatively impacted by parasites and infectious diseases. Bacterial infections are the most important diseases of emergent Canadian aquaculture species such as lumpfish (Cyclopterus lumpus) and sablefish (Anoplop...
| Main Author: | |
|---|---|
| Format: | Text |
| Language: | unknown |
| Published: |
Memorial University of Newfoundland
2020
|
| Subjects: | |
| Online Access: | https://dx.doi.org/10.48336/9erv-8613 https://research.library.mun.ca/14848/ |
| Summary: | Although aquaculture is the fastest growing food-producing industry in the world, it is negatively impacted by parasites and infectious diseases. Bacterial infections are the most important diseases of emergent Canadian aquaculture species such as lumpfish (Cyclopterus lumpus) and sablefish (Anoplopoma fimbria). Aeromonas salmonicida and Vibrio anguillarum, both Gram-negative pathogens, are the most prevalent infectious diseases agents affecting lumpfish aquaculture in the North Atlantic, meanwhile A. salmonicida is the most common pathogen in the sablefish aquaculture industry in the Pacific coast. Comparative genomic analysis of V. anguillarum and A. salmonicida isolates from lumpfish and sablefish outbreaks, respectively, can provide insights into bacterial evolution and virulence, and contribute to effective vaccine design programs. Currently, there are no commercial vaccines available specifically for lumpfish against V. anguillarum, and for sablefish against A. salmonicida. Therefore, the objectives of this study were to: i) analyze the genome and phenotype of V. anguillarum strain J360 isolated from infected lumpfish (Chapter 2); and ii) develop an infection model for atypical A. salmonicida strain J410 in sablefish to evaluate commercial vaccines and an autogenous vaccine (Chapter 3) |
|---|